Roche has confirmed plans to raise its dividend this year against a background of higher sales in the first quarter and regulatory approvals for three new indications for its cancer medicines in the US and drug approvals in cancer and haemophilia in the EU.
The Swiss company declared a dividend of CHF 8.70 per share for 2018.